News Releases

News Releases

April 10, 2023

NervGen Pharma Appoints Michael Kelly as President & Chief Executive Officer

March 30, 2023

NervGen Pharma Reports 2022 Year End Results and Provides Operational Update Including Plans to Initiate Phase 1b/2a Clinical Trial of Proprietary NVG-291 in Q3 2023

February 23, 2023

NervGen Pharma Grants Stock Options

February 14, 2023

NervGen Pharma Announces Completion of Dosing of All Subjects in Phase 1 Clinical Trial of Proprietary Drug Candidate NVG-291

November 17, 2022

NervGen Pharma Announces Composition of Matter Patent for NVG-291 Granted by the US Patent and Trade Office

November 15, 2022

NervGen Pharma Grants Stock Options

November 14, 2022

NervGen Pharma Completes Dosing in its Third Multiple Ascending Dose Cohort in Phase 1 Clinical Trial of NVG-291 and Reports Q3 2022 Results

October 31, 2022

NervGen Engages Cloutier Consulting to Provide Media Relations Services

October 25, 2022

NervGen Pharma Receives FDA Authorization to Expand Enrollment of Males and Premenopausal Females in Phase 1 Clinical Trial of NervGen’s NVG-291

October 20, 2022

NervGen Pharma Presenting at Upcoming Scientific Meetings

Articles

The controversy around falsified Alzheimer’s research

October 24, 2022

NervGen is featured in Health Europa.

Peptide Promotes Nervous System Repair in Stroke Animal Models

July 29, 2022

Read about NervGen in this article in Genetic Engineering and Biotechnology News

With Some Help, Small Canadian Biotech Could Challenge Roche's Hold in Stroke Treatment

July 29, 2022

Read about NervGen and our preclinical results in stroke in this article in BioSpace

Media

Grit Daily Startup

July 4, 2022

Paul Brennan, NervGen President & CEO is interviewed by Stebastian Rusk of the Grit Daily Startup podcast.

Midas Letter Live

February 11, 2022

Interview with Paul Brennan, NervGen President & CEO (Interview at 29:22 in video)

Big Business Show

June 30, 2021

Bob Sullivan, Big Business Show, interviews Paul Brennan.

NervGen (TSX-V: NGEN, OTCQB: NGENF) is a clinical-stage biotech company dedicated to developing innovative treatments to enable nervous system repair in the settings of traumatic injury and disease. NervGen’s lead drug candidate, NVG-291, is being evaluated in a Phase 1b/2a clinical trial in the company’s initial target indication, spinal cord injury. NervGen has initiated preclinical evaluation of a new development candidate, NVG-300, in models of ischemic stroke, amyotrophic lateral sclerosis (ALS) and spinal cord injury.

Contact

112-970 Burrard Street
Unit 1290
Vancouver, BC V6Z 2R4

Phone: (778) 731-1711
Email: info@nervgen.com

Subscribe for Updates